BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19341717)

  • 1. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
    Blanchet B; Saboureau C; Benichou AS; Billemont B; Taieb F; Ropert S; Dauphin A; Goldwasser F; Tod M
    Clin Chim Acta; 2009 Jun; 404(2):134-9. PubMed ID: 19341717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
    Zhen Y; Thomas-Schoemann A; Sakji L; Boudou-Rouquette P; Dupin N; Mortier L; Vidal M; Goldwasser F; Blanchet B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jun; 928():93-7. PubMed ID: 23602929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.
    Qiu F; Bian W; Li J; Ge Z
    Biomed Chromatogr; 2013 May; 27(5):615-21. PubMed ID: 23108983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
    Faivre L; Gomo C; Mir O; Taieb F; Schoemann-Thomas A; Ropert S; Vidal M; Dusser D; Dauphin A; Goldwasser F; Blanchet B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2345-50. PubMed ID: 21737360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
    Rais R; Zhao M; He P; Xu L; Deeken JF; Rudek MA
    Biomed Chromatogr; 2012 Nov; 26(11):1315-24. PubMed ID: 22259028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
    Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
    Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
    Etienne-Grimaldi MC; Renée N; Izzedine H; Milano G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3757-61. PubMed ID: 19797000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a high-performance liquid chromatography ultraviolet method for lapatinib quantification in human plasma.
    Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
    Ther Drug Monit; 2013 Dec; 35(6):796-802. PubMed ID: 23942544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
    Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
    Ther Drug Monit; 2015 Apr; 37(2):172-9. PubMed ID: 25072946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
    Haznedar JO; Patyna S; Bello CL; Peng GW; Speed W; Yu X; Zhang Q; Sukbuntherng J; Sweeny DJ; Antonian L; Wu EY
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):691-706. PubMed ID: 19169880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
    Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
    Ther Drug Monit; 2014 Jun; 36(3):317-25. PubMed ID: 24365980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
    Minkin P; Zhao M; Chen Z; Ouwerkerk J; Gelderblom H; Baker SD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct; 874(1-2):84-8. PubMed ID: 18823825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
    de Bruijn P; Sleijfer S; Lam MH; Mathijssen RH; Wiemer EA; Loos WJ
    J Pharm Biomed Anal; 2010 Mar; 51(4):934-41. PubMed ID: 19931354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An HPLC method for simultaneous quantification of sunitinib and its active metabolite, SU12662, using hydrophilic interaction chromatography principle.
    Gurjar M; Mehta P; Sharma J; Patil S; Kulkarni P; Patil A; Nookala M; Joshi A; Gota V
    Bioanalysis; 2020 Jan; 12(2):75-85. PubMed ID: 31928228
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
    Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
    Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples.
    Velpandian T; Mathur R; Agarwal NK; Arora B; Kumar L; Gupta SK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 May; 804(2):431-4. PubMed ID: 15081939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies.
    Chen X; Wang Z; Liu M; Liao M; Wang X; Du H; Chen J; Yao M; Li Q
    Biomed Chromatogr; 2015 May; 29(5):679-88. PubMed ID: 25294592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
    Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
    Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.